Medpace Historical Income Statement

MEDP Stock

USD 338.96 0.00 0.00%

Historical analysis of Medpace Holdings income statement accounts such as Selling And Marketing Expenses of 840 K can show how well Medpace Holdings performed in making a profits. Evaluating Medpace Holdings income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Medpace Holdings's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Medpace Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Medpace Holdings is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medpace Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Medpace Stock, please use our How to Invest in Medpace Holdings guide.

About Medpace Income Statement Analysis

Medpace Holdings Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Medpace Holdings shareholders. The income statement also shows Medpace investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Medpace Holdings Income Statement Chart

At this time, Medpace Holdings' Net Income is relatively stable compared to the past year. As of 11/28/2024, Income Tax Expense is likely to grow to about 55.5 M, while Selling And Marketing Expenses is likely to drop slightly above 840 K.

Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit Research Development

Total Revenue

Total revenue comprises all receipts Medpace Holdings generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Medpace Holdings minus its cost of goods sold. It is profit before Medpace Holdings operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Medpace Holdings' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Medpace Holdings current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medpace Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Medpace Stock, please use our How to Invest in Medpace Holdings guide.At this time, Medpace Holdings' Net Income is relatively stable compared to the past year. As of 11/28/2024, Income Tax Expense is likely to grow to about 55.5 M, while Selling And Marketing Expenses is likely to drop slightly above 840 K.

	2021	2022	2023	2024 (projected)
Gross Profit	328.2M	432.4M	524.5M	278.6M
Total Revenue	1.1B	1.5B	1.9B	2.0B

Gross Profit Total Revenue

Medpace Holdings income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Tax Provision	Interest Income	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.26	-0.27	-0.25	-0.33	-0.3	-0.31	-0.43	-0.43	-0.31	-0.35	0.2	-0.47	-0.69	-0.44	-0.53	-0.34	-0.36	0.36	-0.41	-0.36	0.43	0.43
Interest Expense	0.26		-0.66	-0.64	-0.68	-0.64	-0.69	-0.67	-0.64	-0.63	-0.69	-0.6	-0.67	0.03	-0.68	-0.63	-0.73	-0.72	0.79	-0.81	-0.78	0.77	0.76
Selling General Administrative	-0.27	-0.66		0.97	0.88	0.98	0.88	0.85	0.84	0.96	0.88	0.86	0.86	0.36	0.87	0.76	0.91	0.96	-0.86	0.83	0.89	-0.84	-0.84
Selling And Marketing Expenses	-0.25	-0.64	0.97		0.86	0.97	0.86	0.84	0.83	0.95	0.86	0.82	0.85	0.4	0.86	0.74	0.89	0.93	-0.84	0.8	0.88	-0.78	-0.81
Total Revenue	-0.33	-0.68	0.88	0.86		0.88	1.0	0.99	0.99	0.87	1.0	0.77	0.98	0.34	0.98	0.94	0.99	0.87	-0.81	0.78	0.92	-0.84	-0.83
Gross Profit	-0.3	-0.64	0.98	0.97	0.88		0.88	0.87	0.86	1.0	0.88	0.83	0.88	0.35	0.89	0.79	0.91	0.94	-0.79	0.77	0.86	-0.8	-0.79
Other Operating Expenses	-0.31	-0.69	0.88	0.86	1.0	0.88		0.98	0.98	0.87	1.0	0.78	0.97	0.32	0.98	0.93	0.98	0.87	-0.82	0.78	0.92	-0.84	-0.83
Operating Income	-0.43	-0.67	0.85	0.84	0.99	0.87	0.98		1.0	0.88	0.99	0.68	1.0	0.4	1.0	0.96	0.98	0.85	-0.78	0.76	0.9	-0.83	-0.8
Ebit	-0.43	-0.64	0.84	0.83	0.99	0.86	0.98	1.0		0.86	0.99	0.68	0.99	0.39	0.99	0.97	0.97	0.84	-0.76	0.74	0.89	-0.81	-0.79
Ebitda	-0.31	-0.63	0.96	0.95	0.87	1.0	0.87	0.88	0.86		0.87	0.81	0.88	0.34	0.89	0.79	0.89	0.92	-0.75	0.73	0.84	-0.78	-0.76
Cost Of Revenue	-0.35	-0.69	0.88	0.86	1.0	0.88	1.0	0.99	0.99	0.87		0.76	0.98	0.35	0.98	0.94	0.99	0.87	-0.82	0.79	0.92	-0.85	-0.84
Total Operating Expenses	0.2	-0.6	0.86	0.82	0.77	0.83	0.78	0.68	0.68	0.81	0.76		0.66	-0.08	0.68	0.58	0.76	0.8	-0.67	0.61	0.72	-0.61	-0.62
Income Before Tax	-0.47	-0.67	0.86	0.85	0.98	0.88	0.97	1.0	0.99	0.88	0.98	0.66		0.46	1.0	0.96	0.98	0.87	-0.81	0.79	0.92	-0.85	-0.83
Total Other Income Expense Net	-0.69	0.03	0.36	0.4	0.34	0.35	0.32	0.4	0.39	0.34	0.35	-0.08	0.46		0.44	0.42	0.39	0.41	-0.46	0.46	0.45	-0.4	-0.42
Net Income	-0.44	-0.68	0.87	0.86	0.98	0.89	0.98	1.0	0.99	0.89	0.98	0.68	1.0	0.44		0.94	0.99	0.87	-0.82	0.8	0.92	-0.87	-0.83
Income Tax Expense	-0.53	-0.63	0.76	0.74	0.94	0.79	0.93	0.96	0.97	0.79	0.94	0.58	0.96	0.42	0.94		0.91	0.82	-0.73	0.69	0.86	-0.72	-0.73
Net Income From Continuing Ops	-0.34	-0.73	0.91	0.89	0.99	0.91	0.98	0.98	0.97	0.89	0.99	0.76	0.98	0.39	0.99	0.91		0.9	-0.87	0.85	0.95	-0.89	-0.87
Tax Provision	-0.36	-0.72	0.96	0.93	0.87	0.94	0.87	0.85	0.84	0.92	0.87	0.8	0.87	0.41	0.87	0.82	0.9		-0.91	0.87	0.93	-0.81	-0.85
Interest Income	0.36	0.79	-0.86	-0.84	-0.81	-0.79	-0.82	-0.78	-0.76	-0.75	-0.82	-0.67	-0.81	-0.46	-0.82	-0.73	-0.87	-0.91		-0.98	-0.94	0.89	0.9
Net Interest Income	-0.41	-0.81	0.83	0.8	0.78	0.77	0.78	0.76	0.74	0.73	0.79	0.61	0.79	0.46	0.8	0.69	0.85	0.87	-0.98		0.92	-0.93	-0.91
Non Operating Income Net Other	-0.36	-0.78	0.89	0.88	0.92	0.86	0.92	0.9	0.89	0.84	0.92	0.72	0.92	0.45	0.92	0.86	0.95	0.93	-0.94	0.92		-0.86	-0.89
Reconciled Depreciation	0.43	0.77	-0.84	-0.78	-0.84	-0.8	-0.84	-0.83	-0.81	-0.78	-0.85	-0.61	-0.85	-0.4	-0.87	-0.72	-0.89	-0.81	0.89	-0.93	-0.86		0.94
Extraordinary Items	0.43	0.76	-0.84	-0.81	-0.83	-0.79	-0.83	-0.8	-0.79	-0.76	-0.84	-0.62	-0.83	-0.42	-0.83	-0.73	-0.87	-0.85	0.9	-0.91	-0.89	0.94

Click cells to compare fundamentals

Medpace Holdings Account Relationship Matchups

Medpace Holdings income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	23.2M	33.5M	37.4M	40.4M	26.3M	34.3M
Interest Expense	1.6M	307K	105K	2.9M	488K	463.6K
Selling General Administrative	94.5M	91.5M	107.2M	130.1M	159.9M	91.4M
Total Revenue	861.0M	925.9M	1.1B	1.5B	1.9B	2.0B
Gross Profit	245.7M	278.7M	328.2M	432.4M	524.5M	278.6M
Other Operating Expenses	733.7M	758.9M	943.8M	1.2B	1.5B	1.6B
Operating Income	127.3M	167.0M	198.6M	278.7M	336.8M	353.7M
Ebit	127.3M	153.1M	182.3M	260.7M	336.8M	353.7M
Ebitda	150.5M	186.6M	219.7M	301.0M	363.2M	186.8M
Cost Of Revenue	615.3M	647.2M	814.2M	1.0B	1.4B	1.4B
Total Operating Expenses	118.4M	111.7M	129.5M	153.7M	187.7M	136.6M
Income Before Tax	124.8M	168.5M	201.9M	282.9M	335.7M	352.5M
Total Other Income Expense Net	(2.4M)	1.5M	3.2M	4.2M	(1.1M)	(1.2M)
Net Income	100.4M	144.9M	181.4M	245.2M	282.8M	297.0M
Income Tax Expense	24.4M	23.1M	20.0M	37.5M	52.9M	55.5M
Net Income From Continuing Ops	100.4M	145.4M	181.8M	245.4M	273.2M	286.8M
Net Income Applicable To Common Shares	100.2M	145.4M	181.8M	245.4M	282.2M	296.3M
Tax Provision	24.4M	23.1M	20.0M	37.5M	45.4M	24.3M
Net Interest Income	(1.6M)	307K	(105K)	(2.9M)	(3.2M)	(3.3M)
Non Operating Income Net Other	(863K)	1.2M	3.3M	7.1M	8.1M	8.5M
Reconciled Depreciation	23.2M	19.5M	21.1M	22.3M	25.3M	22.5M

Pair Trading with Medpace Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medpace Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medpace Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving against Medpace Stock

0.35	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.34	DRUG	Bright Minds Biosciences	Pair Corr
0.33	NBY	NovaBay Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Medpace Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medpace Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medpace Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medpace Holdings to buy it.

The correlation of Medpace Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medpace Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medpace Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medpace Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Medpace Stock Analysis

When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Medpace Historical Income Statement

About Medpace Income Statement Analysis

Medpace Holdings Income Statement Chart

Total Revenue

Gross Profit

Medpace Holdings income statement Correlations

Medpace Holdings Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Medpace Holdings income statement Accounts

Pair Trading with Medpace Holdings

Moving against Medpace Stock

Additional Tools for Medpace Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Ebitda	+ 1.0	Gross Profit
Cost Of Revenue	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Net Interest Income	- 0.98	Interest Income
Non Operating Income Net Other	- 0.94	Interest Income
Reconciled Depreciation	- 0.93	Net Interest Income
Extraordinary Items	- 0.91	Net Interest Income
Interest Income	- 0.91	Tax Provision
Extraordinary Items	- 0.89	Non Operating Income Net Other